Long-term persistence of RBD

Adult Aged Aged, 80 and over Antibodies, Neutralizing / blood Asymptomatic Diseases COVID-19 / immunology Female Humans Limit of Detection Male Memory B Cells / metabolism Middle Aged Neutralization Tests Protein Domains / immunology SARS-CoV-2 / isolation & purification Severity of Illness Index Spike Glycoprotein, Coronavirus / chemistry Time Factors Young Adult
COSIN COVID RBD RBD tetramer SARS-CoV-2 SARS-CoV-2 pseudovirus functional MBCs longitudinal tracking memory B cells neutralizing antibodies

Journal

Cell reports. Medicine
ISSN: 2666-3791
Titre abrégé: Cell Rep Med
Pays: United States
ID NLM: 101766894

Informations de publication

Date de publication:
20 04 2021
Historique:
received: 25 10 2020
revised: 08 02 2021
accepted: 09 03 2021
pubmed: 23 3 2021
medline: 23 3 2021
entrez: 22 3 2021
Statut: ppublish

Résumé

Considerable concerns relating to the duration of protective immunity against severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) exist, with evidence of antibody titers declining rapidly after infection and reports of reinfection. Here, we monitor the antibody responses against SARS-CoV-2 receptor-binding domain (RBD) for up to 6 months after infection. While antibody titers are maintained, ∼13% of the cohort's neutralizing responses return to background. However, encouragingly, in a selected subset of 13 participants, 12 have detectable RBD-specific memory B cells and these generally are increasing out to 6 months. Furthermore, we are able to generate monoclonal antibodies with SARS-CoV-2 neutralizing capacity from these memory B cells. Overall, our study suggests that the loss of neutralizing antibodies in plasma may be countered by the maintenance of neutralizing capacity in the memory B cell repertoire.

Identifiants

DOI: 10.1016/j.xcrm.2021.100228 PMID: 33748788 PMC: PMC7955929
pubmed: 33748788
doi: 10.1016/j.xcrm.2021.100228
pii: S2666-3791(21)00044-6
pmc: PMC7955929
doi:

Substances chimiques

Antibodies, Neutralizing 0
Spike Glycoprotein, Coronavirus 0
spike protein, SARS-CoV-2 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Pagination

100228

Informations de copyright

© 2021 The Author(s).

Déclaration de conflit d'intérêts

The authors declare no competing interests.

Auteurs

Arunasingam Abayasingam (A)

School of Medical Sciences, Faculty of Medicine, UNSW Australia, Sydney, NSW, Australia.
The Kirby Institute, UNSW Australia, Sydney, NSW, Australia.

Harikrishnan Balachandran (H)

School of Medical Sciences, Faculty of Medicine, UNSW Australia, Sydney, NSW, Australia.
The Kirby Institute, UNSW Australia, Sydney, NSW, Australia.

David Agapiou (D)

The Kirby Institute, UNSW Australia, Sydney, NSW, Australia.

Mohamed Hammoud (M)

The Kirby Institute, UNSW Australia, Sydney, NSW, Australia.

Chaturaka Rodrigo (C)

School of Medical Sciences, Faculty of Medicine, UNSW Australia, Sydney, NSW, Australia.
The Kirby Institute, UNSW Australia, Sydney, NSW, Australia.

Elizabeth Keoshkerian (E)

The Kirby Institute, UNSW Australia, Sydney, NSW, Australia.

Hui Li (H)

The Kirby Institute, UNSW Australia, Sydney, NSW, Australia.

Nicholas A Brasher (NA)

School of Medical Sciences, Faculty of Medicine, UNSW Australia, Sydney, NSW, Australia.
The Kirby Institute, UNSW Australia, Sydney, NSW, Australia.

Daniel Christ (D)

Garvan Institute of Medical Research, 384 Victoria Street, Darlinghurst 2010, NSW, Australia.

Romain Rouet (R)

Garvan Institute of Medical Research, 384 Victoria Street, Darlinghurst 2010, NSW, Australia.

Deborah Burnet (D)

Garvan Institute of Medical Research, 384 Victoria Street, Darlinghurst 2010, NSW, Australia.

Branka Grubor-Bauk (B)

Virology Laboratory, Discipline of Surgery, The University of Adelaide and Basil Hetzel Institute for Translational Health Research, Adelaide 5011, SA, Australia.

William Rawlinson (W)

School of Medical Sciences, Faculty of Medicine, UNSW Australia, Sydney, NSW, Australia.
Serology and Virology Division, Department of Microbiology, NSW Health Pathology, Prince of Wales Hospital, Sydney, NSW, Australia.

Stuart Turville (S)

The Kirby Institute, UNSW Australia, Sydney, NSW, Australia.

Anupriya Aggarwal (A)

The Kirby Institute, UNSW Australia, Sydney, NSW, Australia.

Alberto Ospina Stella (AO)

The Kirby Institute, UNSW Australia, Sydney, NSW, Australia.

Christina Fichter (C)

The Kirby Institute, UNSW Australia, Sydney, NSW, Australia.

Fabienne Brilot (F)

Faculty of Medicine and Health, School of Medical Sciences, The University of Sydney, Sydney, NSW, Australia.
Brain Autoimmunity Group, Kids Neurosciences Centre, Kids Research at the Children's Hospital at Westmead, Sydney, NSW, Australia.

Michael Mina (M)

Northern Beaches Hospital, Sydney, NSW, Australia.

Jeffrey J Post (JJ)

Prince of Wales Clinical School, UNSW Australia, Sydney, NSW Australia.

Bernard Hudson (B)

Royal North Shore Hospital, Sydney, NSW, Australia.

Nicky Gilroy (N)

Westmead Hospital, Sydney, NSW, Australia.

Dominic Dwyer (D)

Westmead Hospital, Sydney, NSW, Australia.

Sarah C Sasson (SC)

The Kirby Institute, UNSW Australia, Sydney, NSW, Australia.

Fiona Tea (F)

Faculty of Medicine and Health, School of Medical Sciences, The University of Sydney, Sydney, NSW, Australia.
Brain Autoimmunity Group, Kids Neurosciences Centre, Kids Research at the Children's Hospital at Westmead, Sydney, NSW, Australia.

Deepti Pilli (D)

Faculty of Medicine and Health, School of Medical Sciences, The University of Sydney, Sydney, NSW, Australia.
Brain Autoimmunity Group, Kids Neurosciences Centre, Kids Research at the Children's Hospital at Westmead, Sydney, NSW, Australia.

Anthony Kelleher (A)

The Kirby Institute, UNSW Australia, Sydney, NSW, Australia.

Nicodemus Tedla (N)

School of Medical Sciences, Faculty of Medicine, UNSW Australia, Sydney, NSW, Australia.

Andrew R Lloyd (AR)

The Kirby Institute, UNSW Australia, Sydney, NSW, Australia.

Marianne Martinello (M)

The Kirby Institute, UNSW Australia, Sydney, NSW, Australia.
Westmead Hospital, Sydney, NSW, Australia.
Blacktown Mt Druitt Hospital, Blacktown, NSW, Australia.

Rowena A Bull (RA)

School of Medical Sciences, Faculty of Medicine, UNSW Australia, Sydney, NSW, Australia.
The Kirby Institute, UNSW Australia, Sydney, NSW, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Long-term persistence of RBD
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Sujet âgé › Long-term persistence of RBD
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Sujet âgé › Sujet âgé de 80 ans ou plus › Long-term persistence of RBD
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Globulines › Sérum-globulines › Immunoglobulines › Anticorps › Anticorps neutralisants › Long-term persistence of RBD
questionsmedicales.fr › États, signes et symptômes pathologiques › Processus pathologiques › Caractéristiques de la maladie › Maladies asymptomatiques › Long-term persistence of RBD
questionsmedicales.fr › Maladies de l'appareil respiratoire › Infections de l'appareil respiratoire › Pneumopathie infectieuse › Pneumopathie virale › COVID-19 › Long-term persistence of RBD
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Long-term persistence of RBD
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Statistiques comme sujet › Sensibilité et spécificité › Limite de détection › Long-term persistence of RBD
questionsmedicales.fr › Systèmes sanguin et immunitaire › Système immunitaire › Leucocytes › Agranulocytes › Lymphocytes › Lymphocytes B › Sous-populations de lymphocytes B › Cellules B mémoire › Long-term persistence of RBD
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Adulte d'âge moyen › Long-term persistence of RBD
questionsmedicales.fr › Techniques d'investigation › Techniques immunologiques › Tests immunologiques › Tests sérologiques › Tests de neutralisation › Long-term persistence of RBD
questionsmedicales.fr › Phénomènes chimiques › Phénomènes biochimiques › Conformation moléculaire › Conformation des protéines › Structure tertiaire des protéines › Domaines protéiques › Long-term persistence of RBD
questionsmedicales.fr › Virus › Virus à ARN › Virus à ARN à brin positif › Nidovirales › Coronaviridae › Coronavirus › Betacoronavirus › Virus du SRAS › SARS-CoV-2 › Long-term persistence of RBD
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Collecte de données › Enquêtes et questionnaires › Enquêtes de santé › Indicateurs d'état de santé › Acuité des besoins du patient › Indice de gravité de la maladie › Long-term persistence of RBD
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines virales › Protéines virales structurales › Protéines de l'enveloppe virale › Protéines de fusion virale › Glycoprotéine de spicule des coronavirus › Long-term persistence of RBD
questionsmedicales.fr › Phénomènes physiques › Temps › Facteurs temps › Long-term persistence of RBD
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Jeune adulte › Long-term persistence of RBD